Loss of heterozygosity of selected tumor suppressor genes in human testicular germ cell tumors

Pathology Research and Practice

Volumn 206, Issue 3, 2010, Pages 163-167

  Vladušić, Tomislav ^a   Hrašćan, Reno ^a   Vrhovac, Ivana ^a   Krušlin, Božo ^b   Gamulin, Marija ^c   Grgić, Mislav ^c   Pećina Šlaus, Nives ^d   Franekić Čolić, Jasna ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

^c KBC Zagreb   (Croatia)

^d UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Loss of heterozygosity; Testicular germ cell tumors; Tumor suppressor genes

Indexed keywords

APC PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE A; PROTEIN P53; UVOMORULIN; WNT PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; EXON; GENE LOSS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEMINOMA; SIGNAL TRANSDUCTION; TESTIS NONSEMINOMA CANCER;

ADOLESCENT; ADULT; CADHERINS; GENES, APC; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 76949102316     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2009.10.007     Document Type: Article

References (23)

1. Bahrami A., Ro J.Y., and Ayala A.G. An overview of testicular germ cell tumors. Arch. Pathol. Lab. Med. 131 (2007) 1267-1280
2. Bergthorsson J.T., Agnarsson B.A., Gudbjartsson T., Magnusson K., Thoroddsen A., Palsson B., Bjornsson J., Stefansson K., Gulcher J., Einarsson G.V., Amundadottir L.T., and Barkardottir R.B. A genome-wide study of allelic imbalance in human testicular germ cell tumors using microsatellite markers. Cancer Genet. Cytogenet. 164 (2005) 1-9
3. Damalas A., Kahan S., Shtutman M., Ben-Ze'ev A., and Oren M. Deregulated β-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 20 (2001) 4912-4922
4. In: Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A., Kleihues P., and Sobin L.H. (Eds). World Health Organization Classification of Tumour (2004), IARC Press, Lyon
5. Engel M., Seifert M., Theisinger B., Seyfert U., and Welter C. Glyceraldehide-3-phosphate dehydrogenase and Nm23-H1/nucleoside diphosphate kinase A. Two old enzymes combine for the novel Nm23 protein phosphotransferase function. J. Biol. Chem. 273 (1998) 20058-20065
6. Fleischhecker M., Strohmeyer T., Imai Y., Slamon D.J., and Koeffler H.P. Mutations of the p53 gene are not detectable in human testicular tumors. Mod. Pathol. 7 (1994) 435-439
7. Guillou L., Estreicher A., Chaubert P., Hurlimann J., Kurt A.-M., Metthez G., Iggo R., Gray A.C., Jichlinski P., Leisinger H.-J., and Benhattar J. Germ cell tumors of the testis overexpress wild-type p53. Am. J. Pathol. 149 (1996) 1221-1228
8. Heidenreich A., Sesterhenn I.A., Mostofi F.K., and Moul J.W. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 83 (1998) 1002-1011
9. Honecker F., K.ersemaekers A.-M.F., Molier M., van Weeren P.C., Stoop H., de Krijger R.R., Wolffenbuttel K.P., Oosterhuis W., Bokemeyer C., and Looijenga L.H.J. Involvement of E-cadherin and β-catenin in germ cell tumours and in normal male fetal germ cell development. J. Pathol. 204 (2004) 167-174
10. Honorio S., Agathanggelou A., Wernert N., Rothe M., Maher E.R., and Latif F. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 22 (2003) 461-466
11. Hori K., Uematsu K., Yasoshima H., Sakurai K., Yamada A., and Ohya M. Immunohictochemical analysis of the nm23 gene products in testicular seminoma. Pathol. Int. 47 (1997) 288-292
12. Hrašćan R., Pećina-Šlaus N., Nikuševa Martić T., Franekić Čolić J., Gall-Trošelj K., Pavelić K., and Karapandža N. Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas. J. Neuroendocrinol. 20 (2008) 1015-1022
13. Jones R.H., and Vasey P.A. New directions in testicular cancer: molecular determinants of oncogenesis and treatment success. Eur. J. Cancer 39 (2003) 147-156
14. Kato N., Shibuya H., Fukase M., Tamura G., and Motoyama T. Involvement of adenomatous polyposis coli (APC) gene in testicular yolk sac tumor of infants. Hum. Pathol. 37 (2006) 48-53
15. L.ooijenga L.H.J., and Oosterhuis J.W. Pathogenesis of testicular germ cell tumours. Rev. Reprod. 4 (1999) 90-100
16. Pećina-Šlaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 3 (2003) 17
17. Peifer M., and Polakis P. Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 287 (2000) 1606-1609
18. Peng H.-Q., Bailey D., Bronson D., Goss P.E., and Hogg D. Loss of heterozygosity of tumor suppressor genes in testis cancer. Cancer Res. 55 (1995) 2871-2875
19. Ridgeway A.G., McMenamin J., and Leder P. P53 levels determine outcome during β-catenin tumor initiation and metastasis in the mammary gland and male germ cells. Oncogene 25 (2006) 3518-3527
20. Rothe M., Albers P., and Wernert N. Loss of heterozygosity, differentiation, and clonality in microdissected male germ cell tumours. J. Pathol. 188 (1999) 389-394
21. Saito T., Katagiri A., Watanabe R., Tanikawa T., Kawasaki T., Tomita Y., and Takahashi K. Expression of E-cadherin and catenins on testis tumor. Urol. Int. 65 (2000) 140-143
22. Schmitd B., Ackermann R., Hartmann M., and Strohmeyer T. Alterations of the metastasis suppressor gene nm23 and the proto-oncogene c-myc in human testicular germ cell tumors. J. Urol. 158 (1997) 2000-2005
23. Sonne S.B., Hoei-Hansen C.E., Nielsen J.E., Herlihy A.S., Andersson A.-M., Almstrup K., Daugaard G., Skakkebaek N.E., Leffers H., and M.eyts E.R.-D. CDH1 (E-cadherin) in testicular germ cell neoplasia: suppressed translation of mRNA in pre-invasive carcinoma in situ but increased protein levels in advanced tumours. APMIS 114 (2006) 549-558